)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nightingale Health
Nightingale Health (HEALTH) investor relations material
Nightingale Health H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary16 Sep, 2026
Executive summary
Transitioned from a technology-focused to a commercially-driven company, emphasizing global expansion and adoption of its preventive healthcare platform, now positioned as a global standard for AI-powered preventive healthcare with multi-disease risk detection from a single blood sample.
Over 3 million samples processed, 1,000+ publications, and regulatory approvals in multiple markets; labs established in Finland, Japan, Singapore, UK, and US, with national use in Finland.
Achieved 17% revenue growth year-over-year to EUR 5.5 million, below the 50% target due to a project delay deferring EUR 2–2.4 million in revenue to the next fiscal year.
Major commercial and research contracts signed, including a EUR 2.4 million multiomics project in Denmark and a EUR 0.7 million contract in Italy.
Expansion into new markets and regulatory milestones, including a clinical laboratory permit in New York and new CCO appointments, strengthened the company’s global position.
Financial highlights
Fiscal year revenue reached EUR 5.5 million, up 17% year-over-year, with the second half up 30% compared to the previous year.
Net loss for the year was EUR -18.47 million, nearly unchanged from the prior year; EBITDA was EUR -11.87 million.
Largest revenue contribution from Research Business, but healthcare segment is growing rapidly.
Net cash at year-end: EUR 32.70 million; liquid funds: EUR 36.80 million; debt-free balance sheet.
Outlook and guidance
Targeting at least EUR 10 million in revenue for the current fiscal year, aiming for approximately 100% growth.
Mid-term goals: agreements to analyze 2 million samples annually in Europe and 10 million in the US or Asia, and to achieve positive EBITDA.
Long-term targets: 100 million samples analyzed and EUR 500 million annual revenue.
Revenue forecast is based on operational sales pipeline, not dependent on large, strategic deals.
Expecting healthcare and research revenue split to approach 50/50 in the near future as healthcare adoption accelerates.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nightingale Health
- H1 revenue rose 4% YoY, with expanded partnerships and US market entry, but net loss widened.HEALTH
H1 2026 - Revenue up 8% to €4.7M, strong liquidity, and major public healthcare and research wins globally.HEALTHH2 2025
- Revenue up 4% to €4.36M; global partnerships and strong cash position drive growth.HEALTHH2 2024
- Revenue up 35%, net loss narrowed, and global expansion advanced with new labs and partnerships.HEALTHH1 2025
Next Nightingale Health earnings date
H1 20279 Mar, 2027
Nightingale Health
Next Nightingale Health earnings date
H1 20279 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nightingale Health Oyj is a Finnish health technology company specializing in preventative health through advanced blood analysis. The company’s proprietary technology measures a wide range of biomarkers from a single blood sample, helping to identify individual disease risks. Nightingale Health provides services for both healthcare professionals and consumers, offering insights that promote better health management and prevention. Its solutions are utilized in healthcare systems and by research organizations globally, including collaborations with major biobanks. Nightingale Health is headquartered in Helsinki, Finland, and its shares are listed on the Nasdaq Helsinki.